U.S. Markets close in 1 hr 21 mins

Top Ranked Momentum Stocks to Buy for December 9th

Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 9th:

Green Brick Partners, Inc. (GRBK): This homebuilding and land development company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.8% over the last 60 days.

Green Brick Partners, Inc. Price and Consensus

Green Brick Partners, Inc. Price and Consensus

Green Brick Partners, Inc. price-consensus-chart | Green Brick Partners, Inc. Quote

Green Brick Partners’ shares gained 5.3% over the last one month more than S&P 500’s gain of 1.9%. The company possesses a Momentum Score of B.

Green Brick Partners, Inc. Price

Green Brick Partners, Inc. Price

Green Brick Partners, Inc. price | Green Brick Partners, Inc. Quote

Intellicheck, Inc. (IDN): This technology company that develops, integrates and markets threat identification and identity authentication solutions has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16% over the last 60 days.

Intellicheck Mobilisa, Inc. Price and Consensus

Intellicheck Mobilisa, Inc. Price and Consensus

Intellicheck Mobilisa, Inc. price-consensus-chart | Intellicheck Mobilisa, Inc. Quote

Intellicheck’s shares gained 13.6% over the last one month. The company possesses a Momentum Score of B.

Intellicheck Mobilisa, Inc. Price

Intellicheck Mobilisa, Inc. Price

Intellicheck Mobilisa, Inc. price | Intellicheck Mobilisa, Inc. Quote

Aquestive Therapeutics, Inc. (AQST): This specialty pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.9% over the last 60 days.

Aquestive Therapeutics, Inc. Price and Consensus

Aquestive Therapeutics, Inc. Price and Consensus

Aquestive Therapeutics, Inc. price-consensus-chart | Aquestive Therapeutics, Inc. Quote

Aquestive Therapeutics’ shares gained 33.8% over the last one month. The company possesses a Momentum Score of A.

Aquestive Therapeutics, Inc. Price

Aquestive Therapeutics, Inc. Price

Aquestive Therapeutics, Inc. price | Aquestive Therapeutics, Inc. Quote

Avadel Pharmaceuticals plc (AVDL): This specialty pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.9% over the last 60 days.

Avadel Pharmaceuticals PLC. Price and Consensus

Avadel Pharmaceuticals PLC. Price and Consensus

Avadel Pharmaceuticals PLC. price-consensus-chart | Avadel Pharmaceuticals PLC. Quote

Avadel Pharmaceuticals’ shares gained 28.6% over the last one month. The company possesses a Momentum Score of A.

Avadel Pharmaceuticals PLC. Price

Avadel Pharmaceuticals PLC. Price

Avadel Pharmaceuticals PLC. price | Avadel Pharmaceuticals PLC. Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

The Hottest Tech Mega-Trend of All                

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Intellicheck Mobilisa, Inc. (IDN) : Free Stock Analysis Report
 
Green Brick Partners, Inc. (GRBK) : Free Stock Analysis Report
 
Avadel Pharmaceuticals PLC. (AVDL) : Free Stock Analysis Report
 
Aquestive Therapeutics, Inc. (AQST) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research